# AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer

Source: https://onco.cc/key-papers/paper-aurelia-jco-2014/  
OnCo record `paper-aurelia-jco-2014` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding bevacizumab to single-agent chemotherapy doubled the time to progression and the response rate in platinum-resistant ovarian cancer, becoming the first regimen to improve outcomes in this hard-to-treat setting.

## Summary

Phase 3 trial of 361 patients with platinum-resistant ovarian cancer (progression within six months of platinum) and up to two prior regimens randomised to weekly paclitaxel, pegylated liposomal doxorubicin or topotecan with or without bevacizumab.

Median progression-free survival was 6.7 versus 3.4 months (hazard ratio 0.48) and objective response 27.3 versus 11.8 percent; overall survival was not significantly improved (16.6 versus 13.3 months), partly because of crossover.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2014
- DOI: 10.1200/JCO.2013.51.4489
- Authors: Pujade-Lauraine E, Hilpert F, Weber B, et al.
- Findings: Median progression-free survival 6.7 vs 3.4 months; hazard ratio 0.48.; Objective response 27.3 percent vs 11.8 percent.
- What it means: Bevacizumab with weekly paclitaxel or other single agents is a standard for platinum-resistant ovarian cancer in bevacizumab-naive patients, and the control regimen for later trials such as MIRASOL and ROSELLA.
- Caveats: No significant overall survival benefit.; Patients with bowel involvement were excluded because of perforation risk.

## Sources

- J Clin Oncol 2014: https://doi.org/10.1200/JCO.2013.51.4489
- PubMed: https://pubmed.ncbi.nlm.nih.gov/24637997/

## Connected records

- cancers: [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-aurelia-jco-2014.json